Curated News
By: NewsRamp Editorial Staff
April 30, 2025
Silo Pharma Reveals Positive Preclinical Results for Ketamine Implant Targeting Fibromyalgia
TLDR
- Silo Pharma's SP-26 offers a safer alternative to opioids, potentially becoming the first at-home injectable ketamine-based therapeutic.
- SP-26 is a novel extended-release ketamine implant for fibromyalgia, designed for subcutaneous delivery with sustained ketamine release for up to 22 days.
- SP-26's advancement as an abuse-deterrent pain therapy could make tomorrow better by providing safer pain relief options and reducing opioid dependency.
- Silo Pharma's SP-26 avoids dissociative effects of IV ketamine and may revolutionize chronic pain management with its time-release implant technology.
Impact - Why it Matters
This news matters as it introduces a potential breakthrough in chronic pain management with the development of an abuse-deterrent ketamine implant. The success of SP-26 in preclinical studies signifies a promising advancement towards providing patients with an effective and safe alternative to traditional pain medications, addressing the urgent need for innovative therapies in the field of fibromyalgia treatment.
Summary
Silo Pharma (NASDAQ: SILO) announced positive preclinical results for its novel extended-release ketamine implant, SP-26, designed to treat fibromyalgia. The study in minipigs demonstrated safety, tolerability, and sustained ketamine release for up to 22 days, supporting SP-26 as a next-generation pain therapy with abuse-deterrent properties. CEO Eric Weisblum highlighted the potential of SP-26 as a safer alternative to opioids, offering chronic pain relief without the dissociative effects of IV ketamine.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Silo Pharma Reveals Positive Preclinical Results for Ketamine Implant Targeting Fibromyalgia
